Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 3147Neoplasms 2478Carcinoma, Non-Small-Cell Lung 1889Prostatic Neoplasms 1645Colorectal Neoplasms 1438Lung Neoplasms 1312Multiple Myeloma 940Neoplasm Metastasis 930Leukemia, Myeloid, Acute 885Pancreatic Neoplasms 862Ovarian Neoplasms 815Melanoma 794Carcinoma, Hepatocellular 745Stomach Neoplasms 650Brain Neoplasms 643Recurrence 642Squamous Cell Carcinoma of Head and Neck 639Head and Neck Neoplasms 613Glioblastoma 575Lymphoma 551Uterine Cervical Neoplasms 549Triple Negative Breast Neoplasms 515Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Carcinoma, Renal Cell 505Endometrial Neoplasms 467Hematologic Neoplasms 466Urinary Bladder Neoplasms 462Colonic Neoplasms 448Sarcoma 439Lymphoma, Non-Hodgkin 439

Interventions

Paracentesis 2irinotecan sucrosofate 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Malignant Ascites × 1 year × Clear all
NCT06432296 2026-05-11

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 3 Active not recruiting
312 enrolled

Malignant Ascites

NCT07490626 2026-03-27

Paracentesis

University of Utah

Phase NA Not yet recruiting
20 enrolled

Malignant Ascites

NCT07397819 2026-02-09

Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy

Sun Yat-sen University

Phase 1/2 Recruiting
48 enrolled

Malignant Ascites

NCT06266091 2025-07-20

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 2 Completed
115 enrolled

Malignant Ascites

NCT07007988 2025-06-06

SIM0388-101

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Recruiting
50 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡